33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Slovin, S. F.; Dorff, T. B.; Falchook, G. S.; Wei, X. X.; Gao, X.; McKay, R. R.; Oh, D. Y.; Wibmer, A. G.; Spear, M. A.; McCaigue, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • PSMAfore: A phase 3 study to compare (177)Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Sartor, A. O.; Morris, M. J.; Chi, K. N.; De Bono, J. S.; Shore, N. D.; Crosby, M.; Kreisl, T. N.; Fizazi, K.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma (mRCC) in the first-line (1L) setting
    Meeting Abstract

    Shah, N. J.; Sura, S.; Shinde, R.; Shi, J.; Perini, R. F.; Puneet, S.; Robert, N. J.; Vogelzang, N. J.; Motzer, R. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Real-world clinical outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) in current immune-oncology (IO) and tyrosine kinase inhibitors (TKIs) era
    Meeting Abstract

    Shah, N. J.; Sura, S.; Shinde, R.; Shi, J. X.; Perini, R. F.; Puneet, S.; Robert, N. J.; Vogelzang, N. J.; Motzer, R. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up
    Meeting Abstract

    Tannir, N. M.; Signoretti, S.; Choueiri, T. K.; McDermott, D. F.; Motzer, R. J.; George, S.; Powles, T.; Donskov, F.; Tykodi, S. S.; Pal, S. K.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinical pharmacology of the antibody-drug conjugate enfortumab vedotin in advanced urothelial carcinoma and other malignant solid tumors
    Meeting Abstract

    Tang, M.; Garg, A.; Bonate, P.; Rosenberg, J. E.; Kadokura, T.; Yamada, A.; Fukushi, R.; Koibuchi, A.; Hanley, W. D.; Poondru, S.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • First look at patient reported outcomes from IRONMAN, the international registry of men with advanced prostate cancer
    Meeting Abstract

    Rencsok, E.; George, D. J.; Kantoff, P. W.; Villanti, P.; Vinson, J.; Gerke, T. A.; Hyslop, T.; Mucci, L. A.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361
    Meeting Abstract

    Powles, T.; Alva, A. S.; Ozguroglu, M.; O'Donnell, P. H.; Loriot, Y.; Csoszi, T.; Vuky, J.; Morales-Barrera, R.; Plimack, E. R.; Matsubara, N.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rao, A.; Heller, G.; Ryan, C. J.; VanderWeele, D. J.; Lewis, L. D.; Tan, A.; Watt, C.; Chen, R. C.; Kohli, M.; Barata, P. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC)
    Meeting Abstract

    Rosenberg, J. E.; Park, S. H.; Dao, T. V.; Castellano, D. E.; Li, J. R.; Mukherjee, S.; Howells, K.; Dry, H.; Lanasa, M. C.; Stewart, R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save